Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,507.69 90.16 0.63%
TOPIX 1,172.65 6.06 0.52%
HANG SENG 22,760.24 64.23 0.28%

BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer



  BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive
  Officer

Business Wire

NEW YORK & PETACH TIKVAH, Israel -- January 28, 2013

BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem
cell technologies for neurodegenerative diseases, announced today that it has
appointed Mr. Alon Natanson as its new Chief Executive Officer (CEO). Mr.
Natanson succeeds Dr. Adrian Harel, who will move into an executive scientific
role in the company.

“Adrian Harel has led BrainStorm through a transforming period in the
company’s history, both in terms of our clinical achievements as well as our
financial security. We are pleased that he will be continuing to serve the
company, albeit in a different capacity,” said Professor Avi Israeli, Chairman
of the Board of Directors.

Prior to joining BrainStorm, Mr. Natanson, 49, successfully led large as well
as early-stage companies in the fields of life science, high-tech, and retail.
Previously, as Director of Marketing and Finance in Teva Pharmaceuticals’
(NYSE:TEVA) Copaxone division, he played a key role in the commercialization
of patented therapeutics for multiple sclerosis, establishing the division and
executing its international strategy and product launch. Mr. Natanson has also
led the successful turnaround of two insolvent American retail companies,
transforming them into growing organizations with substantial gross margins.
Since 2008, he served as President and CEO of Procognia (TASE: PRCG), a
biotechnology company specializing in glycobiology and biopharmaceutical
analytics.

“We are delighted to have Alon Natanson on board and warmly welcome him to
BrainStorm,” added Professor Israeli. “We have full confidence in his
leadership abilities to steer the company to successful completion of clinical
development, regulatory approval and commercialization of our technology.”

“BrainStorm’s remarkable achievements to date demonstrate the company’s
excellent scientific team and the huge potential of their technology,”
commented Mr. Natanson. “I am excited to join the company at this critical
stage, as its breakthrough stem cell candidate gets closer to becoming a part
of tomorrow’s medicine.”

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived from
autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company holds the rights to develop and commercialize its NurOwn
technology through an exclusive, worldwide licensing agreement with Ramot, the
technology transfer company of Tel Aviv University. For more information,
visit the company’s website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements.
Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”,
“likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar
terms and phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation, risks
associated with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key executives and
on its scientific consultants; ability to obtain required regulatory
approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These
factors should be considered carefully, and readers should not place undue
reliance on BrainStorm’s forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press release.
We do not assume any obligation to update forward-looking statements to
reflect actual results or assumptions if circumstances or management’s
beliefs, expectations or opinions should change, unless otherwise required by
law. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.

Contact:

BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Alon Natanson, CEO
Phone: +972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement